People · Operator

Alan V. Levin

Named in public records as an officer, director or promoter · active 2023–2023 · Biotechnology

1
Companies
1
Filings
$28.4M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Tangen Biosciences, Inc.BiotechnologySeries A$28.4M$4.1M2023
Operator network

Alan V. Levin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Dan Wagner · 4 companies · 1 sharedDan WagnerChristopher Benoit · 3 companies · 1 sharedChristopher BenoitChristopher McLeod · 3 companies · 1 sharedChristopher McLeodDaniel V. Wagner · 2 companies · 1 sharedDaniel V. WagnerJohn Davidson · 2 companies · 1 sharedJohn DavidsonBrian Chirico · 1 companies · 1 sharedBrian ChiricoChristopher V. McLeod · 1 companies · 1 sharedChristopher V. Mc…John Nobile · 1 companies · 1 sharedJohn NobileJohn Richard Davidson · 1 companies · 1 sharedJohn Richard Davi…John Richard Nobile · 1 companies · 1 sharedJohn Richard Nobi…John V. Davidson · 1 companies · 1 sharedJohn V. DavidsonRichard Birkmeyer, PhD · 1 companies · 1 sharedRichard Birkmeyer…Richard C. Birkmeyer, PhD · 1 companies · 1 sharedRichard C. Birkme…Vance V. Kershner · 1 companies · 1 sharedVance V. KershnerTangen Biosciences, Inc. · $28.4M raisedTangen Biosciences, I…Alan V. LevinAL
Alan V. Levin Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Alan V. Levin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Dan Wagner14
Christopher McLeod13
Christopher Benoit13
Daniel V. Wagner12
John Davidson12
Christopher V. McLeod11
John V. Davidson11
Brian Chirico11
Richard Birkmeyer, PhD11
John Nobile11
John Richard Nobile11
John Richard Davidson11
Richard C. Birkmeyer, PhD11
Vance V. Kershner11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.